Results 151 to 160 of about 109,952 (303)

FVIIIa Mimetics: New Approaches and Next‐Generation Initiatives

Haemophilia, EarlyView.
ABSTRACT Emicizumab has revolutionized hemophilia A care, yet limitations regarding the “ceiling” of hemostatic efficacy (equivalent to mild hemophilia) and global access persist. This review critically examines two distinct paradigms shaping the future of care: Innovation and Access. Regarding innovation, we synthesize the latest clinical data on next‐
Tadashi Matsushita, Keiji Nogami, Chandrakala Shanmukhaiah   +2 more
wiley   +1 more source

Congenital Factor X-Riyadh (Stuart-Prower) Deficiency With Isolated Prothrombin Time Prolongation: A Case Report. [PDF]

Cureus, 2023
Alasmari BG, Tahaelbashir SE, Alomari M, Hommadi AM, Baothman A, Al-Tala SM.   +5 more
europepmc   +1 more source

Rare Bleeding Disorders and Bleeding Disorder of Unknown Cause: Current Understanding and Recent Developments

Haemophilia, EarlyView.
ABSTRACT Rare bleeding disorders (RBDs) represent a diverse group of inherited conditions involving coagulation factors or platelets. These conditions, such as Glanzmann thrombasthenia (GT) or severe coagulation factor deficiencies, are uncommon. In contrast, bleeding disorder of unknown cause (BDUC) is a diagnosis of exclusion without an identifiable ...
Alessandro Casini, Robert Klamroth, Bauke Haisma, Dino Mehic, Saskia E. M. Schols   +4 more
wiley   +1 more source

Data mining for prothrombin time and international normalized ratio reference intervals in children. [PDF]

PLoS One, 2022
Shaikh MS, Ahmed S.
europepmc   +1 more source

The Swiss Haemophilia Registry–Report From the First 8 Years

Haemophilia, EarlyView.
ABSTRACT Introduction Patient registries capture disease related information and provide a valuable source for real‐world data on rare diseases and their management. The Swiss Haemophilia Registry (SHR) was established in 2015 on the basis of a new Swiss federal human research act.
Alessandra Bosch, Lorenzo Alberio, Pierre Fontana, Lukas Graf, Johanna A. Kremer Hovinga, Nicolas von der Weid, Mattia Rizzi, Manuela Albisetti, the Swiss Haemophilia Network   +8 more
wiley   +1 more source

Maternal prothrombin time as an independent predictor of neonatal sepsis: A retrospective case-control study. [PDF]

PLoS One
Karakelleoğlu G, Kırımlı Yanık ECN, Bozdağ Ş.   +2 more
europepmc   +1 more source

Anemia-Associated Platelets and Plasma Prothrombin Time Increase in Patients with Adenomyosis. [PDF]

J Clin Med, 2022
Lin Q, Li T, Ding S, Yu Q, Zhang X.
europepmc   +1 more source

Real‐World Use of Emicizumab in Patients With Acquired Haemophilia A: An Interim Safety Analysis of a Large‐Scale Post‑Marketing Surveillance Study

Haemophilia, EarlyView.
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima, Katsuyuki Fukutake, Yoshiyuki Ogawa, Yuta Kamei, Chiaki Sugita, Akinori Yuri, Ryota Kobayashi, Akiko Ioka, Tadashi Matsushita   +8 more
wiley   +1 more source

Diagnostic accuracy of Clauss and prothrombin time-derived fibrinogen against rotational thromboelastometry FIBTEM-A5. [PDF]

Res Pract Thromb Haemost
Latona A, Hill K, Rane M, Ho A, Mitra B.
europepmc   +1 more source

A super-geriatric patient with gastrostomy underwent life-threatening prothrombin time-international normalized ratio prolongation by warfarin following fasting and antibiotic therapy. [PDF]

Clin Case Rep, 2023
Saeki M, Watanabe A, Momo K, Kashiwabara Y, Iha T, Nagata T, Fujiwara A, Tanaka K.   +7 more
europepmc   +1 more source